WebAug 18, 2024 · ClinicalTrials.gov Identifier: NCT05011513 Other Study ID Numbers: C4671002 2024-002857-28 ( EudraCT Number ) EPIC-SR ( Other Identifier: Alias Study Number ) First Posted: August 18, 2024 Key Record Dates: Last Update Posted: December 12, 2024 Last Verified: December 2024 WebApr 12, 2024 · The National Cancer Institute, part of the National Institutes of Health (NIH), has helped launch a phase 3 randomized clinical trial (NCT05633602) of a two-drug combination to treat patients with advanced non-small cell lung cancer (NSCLC).Called the Pragmatica-Lung Study (or S2302), this is one of the first NCI-supported clinical trials …
Pragmatica-Lung Study, a streamlined model for future cancer …
WebJul 11, 2024 · ClinicalTrials.gov Identifier: NCT03212404 Other Study ID Numbers: CK-301-101 : First Posted: July 11, 2024 Key Record Dates: Last Update Posted: March 4, 2024 Last Verified: March 2024 Layout table for additional information; Studies a U.S. FDA-regulated Drug Product: ... WebDec 10, 2024 · ClinicalTrials.gov Identifier: NCT05153330 Other Study ID Numbers: COVALENT-101 : First Posted: December 10, 2024 Key Record Dates: Last Update Posted: February 27, 2024 Last Verified: February 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No: Layout table for additional information ... pheobe tewwg
How to Apply for a PRS Account - ClinicalTrials.gov
WebApr 13, 2024 · ClinicalTrials.gov Identifier: NCT05811481 Other Study ID Numbers: [2024]662 : First Posted: April 13, 2024 Key Record Dates: Last Update Posted: April 13, 2024 Last Verified: April 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No: Plan Description: ... WebApr 7, 2024 · ClinicalTrials.gov Identifier: NCT04336982 Other Study ID Numbers: CC-90009-AML-002 U1111-1247-5619 ( Other Identifier: WHO ) 2024-001681-15 ( EudraCT Number ) First Posted: April 7, 2024 Key Record Dates: Last Update Posted: March 10, 2024 Last Verified: March 2024 ... WebApr 14, 2024 · A clinical answer successful induction therapy will be set according to the maximum temperature (ºC) daily 72 hours and no increase in the severity of clinical signs, symptoms or laboratory abnormalities attributable to histoplasmosis (e.g., weight instabilities (kg), blood pressure (mmHg) and blood oxygen level (mg/L)).The primary outcome will … pheobe tucker cairns